April 18, 2024Open Access

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

NLN. LamichhaneTianjin University of Traditional Chinese Medicine NMNikolaos MelasÖrebro University VBViktoria BergqvistLund University

Key Points

Key points are not available for this paper at this time.

Abstract

Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Lamichhane et al. (Thu,) studied this question.

synapsesocial.com/papers/68e6e8afb6db643587663c92 https://doi.org/https://doi.org/10.1007/s10620-024-08422-9

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Estimation of Average Concentration in the Presence of Nondetectable Values1990 · 3,459 citations
2The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases2009 · 460 citations
3EuroQol - a new facility for the measurement of health-related quality of life1990 · 15,875 citations
4Crohn's disease2016 · 2,639 citations
5The Short Health Scale: A valid measure of subjective health in ulcerative colitis2006 · 125 citations

AI에게 질문

Bookmark

View Full Paper